Cargando…
Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review
Diabetes is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) in which dyslipidaemia plays a crucial role. Statins are first line therapy for primary and secondary prevention of ASCVD; however, adverse events include reversible musculoskeletal and liver side effects in addition...
Autores principales: | Alam, Uazman, Al-Bazz, Dalal Y., Soran, Handrean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266948/ https://www.ncbi.nlm.nih.gov/pubmed/34037950 http://dx.doi.org/10.1007/s13300-021-01070-6 |
Ejemplares similares
-
Bempedoic acid for the treatment of dyslipidemia
por: Marrs, Joel C, et al.
Publicado: (2020) -
Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
por: Pradhan, Akshyaya, et al.
Publicado: (2023) -
An Update on New Cholesterol Inhibitor: Bempedoic Acid
por: Kulshreshtha, Mayank
Publicado: (2022) -
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia
por: Jadhav, Satyawan B., et al.
Publicado: (2023) -
Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events
por: Jialal, Ishwarlal, et al.
Publicado: (2023)